Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ226MR)

This product GTTS-WQ226MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ226MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ404MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ12489MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ6159MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ14310MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ12941MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ44MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ720MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ14697MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW